Alectos Therapeutics
Pharmaceutical Manufacturing • 
Burnaby, British Columbia, Canada • 11-20 Employees
Company overview
| Headquarters | 8999 Nelson Way, Burnaby, B.C. V5A 4B5, CA |
| Phone number | +16046287129 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Drug Discovery, Traumatic Brain Injury, Alzheimer'S Disease, Parkinson'S Disease, Target Validation, Small-Molecule Therapeutics, Batten Disease, Acute Ischemic Stroke, Niemann-Pick Type C Disease |
| Founded | 2007 |
| Employees | 11-20 |
| Socials |
Key Contact at Alectos Therapeutics
Yuanxi Zhou
Director Of Medicinal Chemistry
Alectos Therapeutics Email Formats
Alectos Therapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About Alectos Therapeutics
Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and preclinical development of novel small-molecule therapeutics for neurological diseases. Alectos focuses on identifying and developing innovative disease-modifying strategies to address complex neurological conditions for which there are no effective treatments, including Alzheimer’s disease, Parkinson’s disease, and acute ischemic stroke. The Alectos pipeline is directed towards the development of new agents to treat patients living with neurological disorders. Our glucocerebrosidase 2 (GBA2) program represents a disease-modifying strategy to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease, Niemann-Pick type C disease, and Batten disease. Our O-GlcNAcase (OGA) program focuses on the development of neuroprotective therapies to counteract the effects of cellular stress in the brain. Alectos partnered with Merck to pioneer the development of the first OGA inhibitor to enter clinical studies. This program has now returned to Alectos, and we are applying our broad intellectual property and deep knowledge in this space to advance our novel OGA inhibitors as disease-modifying treatments for neurodegenerative diseases including AD/PD, as well as for acute conditions such as ischemic stroke and traumatic brain injury. We welcome partnership inquiries regarding our OGA and GBA2 programs.
Alectos Therapeutics revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $63,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,200,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Alectos Therapeutics has 9 employees across 4 departments.
Departments
Number of employees
Funding Data
Alectos Therapeutics has never raised funding before.
Alectos Therapeutics Tech Stack
Discover the technologies and tools that power Alectos Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Video players
JavaScript libraries
JavaScript libraries
Analytics
JavaScript libraries
Font scripts
JavaScript libraries
Web servers
Miscellaneous
Programming languages
Blogs
Saudi Arabia
United States
Finland
United Kingdom
South Africa
Netherlands
Frequently asked questions
4.8
40,000 users
